The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback